Ito Fumito, Agni Rashmi, Rettammel Robert J, Been Mark J, Cho Clifford S, Mahvi David M, Rikkers Layton F, Weber Sharon M
Department of Surgery, Section of Surgical Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792, USA.
Ann Surg. 2008 Aug;248(2):273-9. doi: 10.1097/SLA.0b013e31817f2bfd.
Hilar cholangiocarcinoma is an uncommon tumor with a poor prognosis. We sought to evaluate recurrence patterns and prognostic factors for disease-specific and disease-free survival in patients with surgically resected hilar cholangiocarcinoma in a single institution over the last 21 years.
From 1985 to 2006, all patients with hilar cholangiocarcinoma referred to a tertiary surgical clinic were evaluated. Demographic data, tumor characteristics, and outcome were analyzed retrospectively. Outcome was compared in patients treated in a recent era (1995-2006) compared with an earlier era (1985-1994).
Of 91 patients evaluated, 22 patients (24%) had unresectable disease at presentation. Of the 69 patients submitted to laparotomy, resection was possible in 55% and the curative (R0) resection rate was 63%. In patients submitted to exploration, the operative (60 day) morbidity and mortality rates were 26% and 3%. Median disease-specific (DSS) and disease-free survival (DFS) were 29 and 20 months, respectively (median FU, 29 months.). In patients undergoing R0 resection, the median survival was prolonged (65 months). In the more recent era, resectability rates improved (69% vs. 17%; P = 0.0002), and this was associated with an improvement in median survival (30 vs. 4 months; P < 0.001). Factors predictive of improved disease-specific and disease-free survival included negative histologic margins, concomitant hepatic lobectomy, lack of nodal disease, well-differentiated histology, and an earlier tumor stage (P < 0.05). Concomitant liver resection was associated with a higher R0 resection rate (P = 0.006) and improved DSS and DFS (P = 0.005). In addition, concomitant liver resection was associated with a decreased incidence of initial recurrence in liver (P = 0.031).
In patients with hilar cholangiocarcinoma, concomitant hepatic resection is associated with improved DFS, DSS, and decreased hepatic recurrence. Therefore, hepatectomy combined with bile duct resection should be considered standard treatment.
肝门部胆管癌是一种罕见的肿瘤,预后较差。我们试图评估过去21年中在单一机构接受手术切除的肝门部胆管癌患者的复发模式以及疾病特异性生存和无病生存的预后因素。
对1985年至2006年转诊至三级外科诊所的所有肝门部胆管癌患者进行评估。回顾性分析人口统计学数据、肿瘤特征和结局。将近期(1995 - 2006年)治疗的患者与早期(1985 - 1994年)治疗的患者的结局进行比较。
在评估的91例患者中,22例(24%)初诊时患有不可切除的疾病。在69例行剖腹手术的患者中,55%可行切除,根治性(R0)切除率为63%。在接受探查的患者中,手术(60天)发病率和死亡率分别为26%和3%。疾病特异性生存(DSS)和无病生存(DFS)的中位数分别为29个月和20个月(中位随访时间,29个月)。在接受R0切除的患者中,中位生存期延长(65个月)。在近期,可切除率有所提高(69%对17%;P = 0.0002),这与中位生存期的改善相关(30个月对4个月;P < 0.001)。预测疾病特异性生存和无病生存改善的因素包括组织学切缘阴性、同期肝叶切除术、无淋巴结疾病、高分化组织学以及较早的肿瘤分期(P < 0.05)。同期肝切除与更高的R0切除率相关(P = 0.006),并改善了DSS和DFS(P = 0.005)。此外,同期肝切除与肝脏初始复发的发生率降低相关(P = 0.031)。
对于肝门部胆管癌患者,同期肝切除与DFS、DSS的改善以及肝脏复发的减少相关。因此,肝切除联合胆管切除应被视为标准治疗。